Page 1

Optiscan Imaging Limited Appendix 4E Preliminary final report 1. Company details Name of entity : ABN : Reporting period : Previous period : Optiscan Imaging Limited 81 077 771 987 For the year ended 30 June 2021 For the year ended 30 June 2020 2. Results for announcement to the market ( OptiScan Revenues from ordinary activities down 25.3 % to 889,526 Loss from ordinary activities after tax attributable to the owners of Optiscan Imaging Limited up 20.5 % to ( 2,126,695 ) Loss for the year attributable to the owners of Optiscan Imaging Limited up 20.5 % to ( 2,126,695 ) Dividends There were no dividends paid , recommended or declared during the current financial period . Comments The loss for the consolidated entity after providing for income tax amounted to $ 2,126,695 ( 30 June 2020 : $ 1,765,353 ) . Financial performance During the financial year ending 30 June 2021 ( FY21 ) , the consolidated entity generated ordinary revenue of $ 889,526 from sales , system rentals and the provision of services ( 2020 : $ 1,190,712 ) and other income of $ 1,651,928 ( 2020 : $ 785,714 ) . Other income comprised $ 511,979 received from the BioMedtech Horizons Program which forms part of the Federal Government's Medical Research Future Fund to support the Oral Cancer Study at the University of Melbourne , Melbourne Dental School ( MDS Oral Cancer Trial ) . The consolidated entity also recorded research and development incentive income of $ 847,324 , an increase of $ 146,082 from the previous corresponding period ( 2020 : $ 701,242 ) . Total expenses for FY21 increased to $ 4,668,149 , an increase of $ 926,370 from the corresponding period ( 2020 : $ 3,741,779 ) . These expenses include those relating to the cost of the MDS Oral Cancer Trial ; preparations for the application to the United States Food & Drug Administration ( FDA ) to market the InVivageⓇ device for sale in the United States ( US based consultants and local and overseas contract testing agencies ) ; and five ( 5 ) additional employees and contractors recruited and engaged during FY21 as the company increased its resources in production , quality assurance and human resources . The net operating cash outflow for FY21 was $ 2,126,309 compared to $ 1,396,563 for the previous financial year . Financial Position The net assets increased by $ 8,668,783 to $ 10,217,106 at 30 June 2021 ( 30 June 2020 : $ 1,548,323 ) . The working capital position of the consolidated entity at 30 June 2021 was an excess of current assets over current liabilities of $ 9,995,498 ( 30 June 2020 : $ 1,264,761 ) . The increase in the net asset position of the consolidated entity was primarily as a result of the capital raising completed by the Company during the financial year amounting to $ 9,813,499 before costs .